Enalapril Clinical Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships

[1]  T. Baussant,et al.  Angiotensin‐Converting Enzyme Inhibition Does Not Suppress Plasma Angiotensin II Increase During Exercise in Humans , 1993, Journal of cardiovascular pharmacology.

[2]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[3]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[4]  J. Reid,et al.  Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers. , 1992, British journal of clinical pharmacology.

[5]  K. Ito,et al.  CIRCULATING ANGIOTENSIN II LEVELS UNDER REPEATED ADMINISTRATION OF LISINOPRIL IN NORMAL SUBJECTS , 1992, Clinical and experimental pharmacology & physiology.

[6]  A. Struthers,et al.  Furosemide‐Induced Natriuresis Is Augmented by Ultra‐Low‐Dose Captopril but Not by Standard Doses of Captopril in Chronic Heart Failure , 1992, Circulation.

[7]  J. Schaper,et al.  Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats , 1992, British journal of pharmacology.

[8]  K. Goa,et al.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. , 1992, Drugs.

[9]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[10]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[11]  Y. Christen,et al.  Determinants of angiotensin II generation during converting enzyme inhibition. , 1990, Hypertension.

[12]  P. Meredith,et al.  Concentration-effect analysis of antihypertensive drug responses. , 1990 .

[13]  K. Takebe,et al.  The pharmacokinetics of enalapril in patients with compensated liver cirrhosis. , 1990, British journal of clinical pharmacology.

[14]  P A Meredith,et al.  Kinetic-dynamic relations and individual responses to enalapril. , 1990, Hypertension.

[15]  P. Meredith,et al.  Prediction of the antihypertensive response to enalapril. , 1989, Journal of hypertension.

[16]  R. Hall,et al.  Captopril and the diuretic requirements in moderate and severe chronic heart failure. , 1989, European heart journal.

[17]  J. Riordan,et al.  Angiotensin-converting enzyme: new concepts concerning its biological role. , 1989, Biochemistry.

[18]  P. Hayes,et al.  Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function. , 1989, Journal of human hypertension.

[19]  T. Ishizaki,et al.  Kinetics and dynamics of enalapril in patients with liver cirrhosis , 1989, Clinical pharmacology and therapeutics.

[20]  K. Takebe,et al.  ENALAPRIL PHARMACOKINETICS IN DIABETIC PATIENTS , 1989, The Lancet.

[21]  J. Cleland,et al.  The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure. , 1988, European heart journal.

[22]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[23]  K. Dickstein,et al.  The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure. , 1987, British journal of clinical pharmacology.

[24]  B. Waeber,et al.  Pharmacokinetics of the Converting Enzyme Inhibitor Cilazapril in Normal Volunteers and the Relationship to Enzyme Inhibition: Development of a Mathematical Model , 1987, Journal of Cardiovascular Pharmacology.

[25]  J. Reid,et al.  Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. , 1986, British journal of clinical pharmacology.

[26]  J. Farmer,et al.  Pharmacokinetics and Pharmacodynamics of Enalapril in Patients with Congestive Heart Failure and Patients with Hypertension , 1985, Journal of cardiovascular pharmacology.

[27]  C. Johnston,et al.  Enalapril (MK421) activation in man: importance of liver status. , 1985, British journal of clinical pharmacology.

[28]  D. Lowenthal,et al.  The clinical pharmacology of antihypertensive drugs. , 1984, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[29]  R. Davies,et al.  Clinical pharmacology of enalapril. , 1984, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[30]  B. Swanson,et al.  Influence of food on the bioavailability of enalapril. , 1984, Journal of pharmaceutical sciences.

[31]  R. Davies,et al.  Enalapril worldwide experience. , 1984, The American journal of medicine.

[32]  H. Holman,et al.  Partial purification and characterization of plasma DNA and its relation to disease activity in systemic lupus erythematosus. , 1984, The American journal of medicine.

[33]  J. Bolognese,et al.  Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. , 1984, Biopharmaceutics & drug disposition.

[34]  C. Johnston,et al.  Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension. , 1984, British journal of clinical pharmacology.

[35]  R. Davies,et al.  An overview of the clinical pharmacology of enalapril. , 1984, British journal of clinical pharmacology.

[36]  H. Rotmensch,et al.  BIOAVAILABILITY OF ENALAPRIL MALEATE , 1984 .

[37]  T. Usherwood,et al.  Factors related to first dose hypotensive effect of captopril: prediction and treatment. , 1983, British medical journal.

[38]  A. Scriabine.  New drugs annual : cardiovascular drugs , 1983 .

[39]  E. Ulm.  Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man. , 1983, Drug metabolism reviews.

[40]  J. Biollaz,et al.  Enalapril maleate and a lysine analogue (MK-521): disposition in man. , 1982, British journal of clinical pharmacology.